Giant cell arteritis: A review of classification, pathophysiology, geoepidemiology and treatment

Autoimmunity Reviews

Volumn 11, Issue 6-7, 2012, Pages

  Borchers, Andrea T ^a   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; FLUORODEOXYGLUCOSE F 18; GAMMA INTERFERON; GLUCOCORTICOID; HLA DRB1 ANTIGEN; INFLIXIMAB; INTERLEUKIN 17; METHOTREXATE; METHYLPREDNISOLONE; TOCILIZUMAB; VITAMIN D;

AVASCULAR NECROSIS; BLOOD VESSEL BIOPSY; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FRAGILITY FRACTURE; GASTROINTESTINAL HEMORRHAGE; GENETIC ASSOCIATION; GEOGRAPHIC DISTRIBUTION; GIANT CELL ARTERITIS; HEART INFARCTION; HISTOPATHOLOGIC SKIN REACTION; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOPATHOGENESIS; INCIDENCE; INFECTION; INTRAVASCULAR ULTRASOUND; ISCHEMIA; LOW DRUG DOSE; MACROPHAGE; MAGNETIC RESONANCE ANGIOGRAPHY; MONOTHERAPY; MORTALITY; OPTIMAL DRUG DOSE; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; REVIEW; SUBCAPSULAR CATARACT; T LYMPHOCYTE; THROMBOCYTE COUNT; VISUAL IMPAIRMENT;

AORTA; AORTIC ANEURYSM; ASPIRIN; AZATHIOPRINE; DENDRITIC CELLS; FEMALE; GIANT CELL ARTERITIS; HUMANS; MACROPHAGES; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; METHOTREXATE; POSITRON-EMISSION TOMOGRAPHY; SEX FACTORS; T-LYMPHOCYTES; TEMPORAL ARTERIES; ULTRASONOGRAPHY;

EID: 84858440886     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.01.003     Document Type: Review

References (150)

1. Assie C., Janvresse A., Plissonnier D., Levesque H., Marie I. Long-term follow-up of upper and lower extremity vasculitis related to giant cell arteritis: a series of 36 patients. Medicine (Baltimore) 2011, 90:40-51.
2. Kermani T.A., Matteson E.L., Hunder G.G., Warrington K.J. Symptomatic lower extremity vasculitis in giant cell arteritis: a case series. J Rheumatol 2009, 36:2277-2283.
3. Smeeth L., Cook C., Hall A.J. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis 2006, 65:1093-1098.
4. Smetana G.W., Shmerling R.H. Does this patient have temporal arteritis?. JAMA 2002, 287:92-101.
5. Gonzalez-Gay M.A., Miranda-Filloy J.A., Lopez-Diaz M.J., Perez-Alvarez R., Gonzalez-Juanatey C., Sanchez-Andrade A., et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore) 2007, 86:61-68.
6. Salvarani C., Crowson C.S., O'Fallon W.M., Hunder G.G., Gabriel S.E. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum 2004, 51:264-268.
7. Abdul-Rahman A.M., Molteno A.C., Bevin T.H. The epidemiology of giant cell arteritis in Otago, New Zealand: a 9-year analysis. N Z Med J 2011, 124:44-52.
8. Hernández-Rodríguez J., García-Martínez A., Casademont J., Filella X., Esteban M.J., López-Soto A., et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 2002, 47:29-35.
9. Khalifa M., Karmani M., Jaafoura N.G., Kaabia N., Letaief A.O., Bahri F. Epidemiological and clinical features of giant cell arteritis in Tunisia. Eur J Intern Med 2009, 20:208-212.
10. Liozon E., Boutros-Toni F., Ly K., Loustaud-Ratti V., Soria P., Vidal E. Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course. J Rheumatol 2003, 30:1272-1276.
11. Salvarani C., Gabriel S.E., O'Fallon W.M., Hunder G.G. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheum 1995, 38:369-373.
12. Elling P., Olsson A.T., Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996, 23:112-119.
13. Gonzalez-Gay M.A., Amoli M.M., Garcia-Porrua C., Ollier W.E. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003, 33:38-48.
14. Lee J.L., Naguwa S.M., Cheema G.S., Gershwin M.E. The geo-epidemiology of temporal (giant cell) arteritis. Clin Rev Allergy Immunol 2008, 35:88-95.
15. Chaudhry I.A., Shamsi F.A., Elzaridi E., Arat Y.O., Bosley T.M., Riley F.C. Epidemiology of giant-cell arteritis in an Arab population: a 22-year study. Br J Ophthalmol 2007, 91:715-718.
16. Pereira L.S., Yoon M.K., Hwang T.N., Hong J.E., Ray K., Porco T., et al. Giant cell arteritis in Asians: a comparative study. Br J Ophthalmol 2011, 95:214-216.
17. Shah A., Jain S. Epidemiology of giant cell arteritis in an Arab population: a 22-year study. Ethnic variation in incidence of giant cell arteritis. Br J Ophthalmol 2008, 92:724-725.
18. Lugo J.Z., Deitch J.S., Yu A., Jang J.H., Patel R., Slova D., et al. Demographic and laboratory data may predict positive temporal artery biopsy. J Surg Res 2011.
19. Östberg G. Temporal arteritis in a large necropsy series. Ann Rheum Dis 1971, 30:224-235.
20. Bas-Lando M., Breuer G.S., Berkun Y., Mates M., Sonnenblick M., Nesher G. The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations. Clin Exp Rheumatol 2007, 25:S15-S17.
21. Salvarani C., Macchioni P., Zizzi F., Mantovani W., Rossi F., Castri C., et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991, 34:351-356.
22. Singh S., Balakrishnan C., Mangat G., Samant R., Bambani M., Kalke S., et al. Giant cell arteritis in Mumbai. J Assoc Physicians India 2010, 58:372-374.
23. Pamuk O.N., Dönmez S., Karahan B., Pamuk G.E., Çakir N. Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: clinical features and epidemiological data. Clin Exp Rheumatol 2009, 27:830-833.
24. Liozon E., Ouattara B., Rhaiem K., Ly K., Bezanahary H., Loustaud V., et al. Familial aggregation in giant cell arteritis and polymyalgia rheumatica: a comprehensive literature review including 4 new families. Clin Exp Rheumatol 2009, 27:S89-S94.
25. Ly K.H., Regent A., Tamby M.C., Mouthon L. Pathogenesis of giant cell arteritis: more than just an inflammatory condition?. Autoimmun Rev 2010, 9:635-645.
26. Lie J.T. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum 1990, 33:1074-1087.
27. Liozon F., Catanzano G. L'artérite temporale de Horton. Etude anatomopathologique en microscopie optique. A propos de 123 biopsies temporales. Rev Med Interne 1982, 3:295-301.
28. Krupa W.M., Dewan M., Jeon M.S., Kurtin P.J., Younge B.R., Goronzy J.J., et al. Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am J Pathol 2002, 161:1815-1823.
29. Ma-Krupa W., Jeon M.S., Spoerl S., Tedder T.F., Goronzy J.J., Weyand C.M. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004, 199:173-183.
30. Pryshchep O., Ma-Krupa W., Younge B.R., Goronzy J.J., Weyand C.M. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 2008, 118:1276-1284.
31. Deng J., Ma-Krupa W., Gewirtz A.T., Younge B.R., Goronzy J.J., Weyand C.M. Toll-like receptors 4 and 5 induce distinct types of vasculitis. Circ Res 2009, 104:488-495.
32. Cid M.C., Campo E., Ercilla G., Palacin A., Vilaseca J., Villalta J., et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment. Arthritis Rheum 1989, 32:884-893.
33. Andersson R., Jonsson R., Tarkowski A., Bengtsson B.A., Malmvall B.E. T cell subsets and expression of immunological activation markers in the arterial walls of patients with giant cell arteritis. Ann Rheum Dis 1987, 46:915-923.
34. Schaufelberger C., Andersson R., Nordborg E., Hansson G.K., Nordborg C., Wahlstrom J. An uneven expression of T cell receptor V genes in the arterial wall and peripheral blood in giant cell arteritis. Inflammation 2008, 31:372-383.
35. Martinez-Taboada V., Hunder N.N., Hunder G.G., Weyand C.M., Goronzy J.J. Recognition of tissue residing antigen by T cells in vasculitic lesions of giant cell arteritis. J Mol Med (Berl) 1996, 74:695-703.
36. Weyand C.M., Schonberger J., Oppitz U., Hunder N.N., Hicok K.C., Goronzy J.J. Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med 1994, 179:951-960.
37. Brack A., Geisler A., Martinez-Taboada V.M., Younge B.R., Goronzy J.J., Weyand C.M. Giant cell vasculitis is a T cell-dependent disease. Mol Med 1997, 3:530-543.
38. Ciccia F., Alessandro R., Rizzo A., Principe S., Raiata F., Cavazza A., et al. Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. Arthritis Rheum 2011, 63:2097-2104.
39. Deng J., Younge B.R., Olshen R.A., Goronzy J.J., Weyand C.M. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010, 121:906-915.
40. Visvanathan S., Rahman M.U., Hoffman G.S., Xu S., Garcia-Martinez A., Segarra M., et al. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis-a prospective longitudinal study. Rheumatology (Oxford) 2011.
41. Weyand C.M., Tetzlaff N., Bjornsson J., Brack A., Younge B., Goronzy J.J. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997, 40:19-26.
42. Kaiser M., Younge B., Bjornsson J., Goronzy J.J., Weyand C.M. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol 1999, 155:765-774.
43. Wagner A.D., Björnsson J., Bartley G.B., Goronzy J.J., Weyand C.M. Interferon-γ-producing T cells in giant cell vasculitis represent a minority of tissue-infiltrating cells and are located distant from the site of pathology. Am J Pathol 1996, 148:1925-1933.
44. Hernández-Rodríguez J., Segarra M., Vilardell C., Sánchez M., García-Martínez A., Esteban M.J., et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003, 107:2428-2434.
45. Field M., Cook A., Gallagher G. Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis. Rheumatol Int 1997, 17:113-118.
46. Emilie D., Liozon E., Crevon M.C., Lavignac C., Portier A., Liozon F., et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum Immunol 1994, 39:17-24.
47. Weyand C.M., Wagner A.D., Bjornsson J., Goronzy J.J. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest 1996, 98:1642-1649.
48. Hernández-Rodríguez J., Segarra M., Vilardell C., Sánchez M., García-Martínez A., Esteban M.J., et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004, 43:294-301.
49. Cid M.C., Font C., Oristrell J., de la Sierra A., Coll-Vinent B., Lopez-Soto A., et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998, 41:26-32.
50. Gonzalez-Gay M.A., Garcia-Porrua C., Llorca J., Hajeer A.H., Branas F., Dababneh A., et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000, 79:283-292.
51. Salvarani C., Della Bella C., Cimino L., Macchioni P., Formisano D., Bajocchi G., et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford) 2009, 48:250-253.
52. Cid M.C., Hernandez-Rodriguez J., Esteban M.J., Cebrian M., Gho Y.S., Font C., et al. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002, 106:1664-1671.
53. Seitz M., Reichenbach S., Bonel H.M., Adler S., Wermelinger F., Villiger P.M. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011, 141:w13156.
54. Sciascia S., Rossi D., Roccatello D. Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. J Rheumatol 2011, 38:2080-2081.
55. Segarra M., Garcia-Martinez A., Sanchez M., Hernandez-Rodriguez J., Lozano E., Grau J.M., et al. Gelatinase expression and proteolytic activity in giant-cell arteritis. Ann Rheum Dis 2007, 66:1429-1435.
56. Rodríguez-Pla A., Bosch-Gil J.A., Rosselló-Urgell J., Huguet-Redecilla P., Stone J.H., Vilardell-Tarres M. Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling. Circulation 2005, 112:264-269.
57. Kaiser M., Weyand C.M., Bjornsson J., Goronzy J.J. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998, 41:623-633.
58. Lozano E., Segarra M., Garcia-Martinez A., Hernandez-Rodriguez J., Cid M.C. Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. Ann Rheum Dis 2008, 67:1581-1588.
59. Cid M.C., Cebrián M., Font C., Coll-Vinent B., Hernández-Rodríguez J., Esparza J., et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis Rheum 2000, 43:184-194.
60. Rittner H.L., Hafner V., Klimiuk P.A., Szweda L.I., Goronzy J.J., Weyand C.M. Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. J Clin Invest 1999, 103:1007-1013.
61. Rittner H.L., Kaiser M., Brack A., Szweda L.I., Goronzy J.J., Weyand C.M. Tissue-destructive macrophages in giant cell arteritis. Circ Res 1999, 84:1050-1058.
62. Wagner A.D., Goronzy J.J., Weyand C.M. Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. J Clin Invest 1994, 94:1134-1140.
63. Weyand C.M., Fulbright J.W., Hunder G.G., Evans J.M., Goronzy J.J. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000, 43:1041-1048.
64. Walvick M.D., Walvick M.P. Giant cell arteritis: laboratory predictors of a positive temporal artery biopsy. Ophthalmology 2011, 118:1201-1204.
65. Gonzalez-Gay M.A., Lopez-Diaz M.J., Barros S., Garcia-Porrua C., Sanchez-Andrade A., Paz-Carreira J., et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore) 2005, 84:277-290.
66. Hayreh S.S., Podhajsky P.A., Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998, 125:509-520.
67. Hayreh S.S., Podhajsky P.A., Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol 1998, 125:521-526.
68. Gonzalez-Gay M.A., Vazquez-Rodriguez T.R., Gomez-Acebo I., Pego-Reigosa R., Lopez-Diaz M.J., Vazquez-Triñanes M.C., et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 2009, 88:227-235.
69. Pfadenhauer K., Roesler A., Golling A. The involvement of the peripheral nervous system in biopsy proven active giant cell arteritis. J Neurol 2007, 254:751-755.
70. Liozon E., Herrmann F., Ly K., Robert P.Y., Loustaud V., Soria P., et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001, 111:211-217.
71. González-Gay M.A., Blanco R., Rodríguez-Valverde V., Martínez-Taboada V.M., Delgado-Rodriguez M., Figueroa M., et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998, 41:1497-1504.
72. Nesher G., Berkun Y., Mates M., Baras M., Nesher R., Rubinow A., et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004, 83:114-122.
73. Hamidou M.A., Batard E., Trewick D., Masseau A., Moreau A., Agard C., et al. Silent versus cranial giant cell arteritis. Initial presentation and outcome of 50 biopsy-proven cases. Eur J Intern Med 2005, 16:183-186.
74. Bossert M., Prati C., Balblanc J.C., Lohse A., Wendling D. Aortic involvement in giant cell arteritis: current data. Joint Bone Spine 2011, 78:246-251.
75. Bongartz T., Matteson E.L. Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol 2006, 18:10-17.
76. Lie J.T. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Semin Arthritis Rheum 1995, 24:422-431.
77. Brack A., Martinez-Taboada V., Stanson A., Goronzy J.J., Weyand C.M. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999, 42:311-317.
78. Schmidt W.A., Seifert A., Gromnica-Ihle E., Krause A., Natusch A. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford) 2008, 47:96-101.
79. Klein R.G., Hunder G.G., Stanson A.W., Sheps S.G. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975, 83:806-812.
80. Marie I., Proux A., Duhaut P., Primard E., Lahaxe L., Girszyn N., et al. Long-term follow-up of aortic involvement in giant cell arteritis: a series of 48 patients. Medicine (Baltimore) 2009, 88:182-192.
81. Czihal M., Tato F., Forster S., Rademacher A., Schulze-Koops H., Hoffmann U. Fever of unknown origin as initial manifestation of large vessel giant cell arteritis: diagnosis by colour-coded sonography and 18-FDG-PET. Clin Exp Rheumatol 2010, 28:549-552.
82. Meller J., Strutz F., Siefker U., Scheel A., Sahlmann C.O., Lehmann K., et al. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging 2003, 30:730-736.
83. Säve-Söderbergh J., Malmvall B.E., Andersson R., Bengtsson B.A. Giant cell arteritis as a cause of death. Report of nine cases. JAMA 1986, 255:493-496.
84. Evans J.M., Bowles C.A., Bjornsson J., Mullany C.J., Hunder G.G. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum 1994, 37:1539-1547.
85. Graham E., Holland A., Avery A., Russell R.W. Prognosis in giant-cell arteritis. Br Med J (Clin Res Ed) 1981, 282:269-271.
86. Nordborg E., Bengtsson B.A. Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy. BMJ 1989, 299:549-550.
87. Mukhtyar C., Guillevin L., Cid M.C., Dasgupta B., de Groot K., Gross W., et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009, 68:318-323.
88. Japanese Circulation Society Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. Circ J 2011, 75:474-503.
89. Mahr A., Saba M., Kambouchner M., Polivka M., Baudrimont M., Brocheriou I., et al. Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better?. Ann Rheum Dis 2006, 65:826-828.
90. Hunder G.G., Bloch D.A., Michel B.A., Stevens M.B., Arend W.P., Calabrese L.H., et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990, 33:1122-1128.
91. Baldursson O., Steinsson K., Bjornsson J., Lie J.T. Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. Arthritis Rheum 1994, 37:1007-1012.
92. Rodríguez-Pla A., Rosselló-Urgell J., Bosch-Gil J.A., Huguet-Redecilla P., Vilardell-Tarres M. Proposal to decrease the number of negative temporal artery biopsies. Scand J Rheumatol 2007, 36:111-118.
93. Gonzalez-Gay M.A., Garcia-Porrua C., Llorca J., Gonzalez-Louzao C., Rodriguez-Ledo P. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum 2001, 30:249-256.
94. Marí B., Monteagudo M., Bustamante E., Pérez J., Casanovas A., Jordana R., et al. Analysis of temporal artery biopsies in an 18-year period at a community hospital. Eur J Intern Med 2009, 20:533-536.
95. Lenton J., Donnelly R., Nash J.R. Does temporal artery biopsy influence the management of temporal arteritis?. QJM 2006, 99:33-36.
96. Davies C., Frost B., Eshan O., McLain A.D., Shandall A. Temporal artery biopsy. .who needs one?. Postgrad Med J 2006, 82:476-478.
97. Poller D.N., van Wyk Q., Jeffrey M.J. The importance of skip lesions in temporal arteritis. J Clin Pathol 2000, 53:137-139.
98. Chakrabarty A., Franks A.J. Temporal artery biopsy: is there any value in examining biopsies at multiple levels?. J Clin Pathol 2000, 53:131-136.
99. Narváez J., Bernad B., Roig-Vilaseca D., García-Gómez C., Gómez-Vaquero C., Juanola X., et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum 2007, 37:13-19.
100. Achkar A.A., Lie J.T., Hunder G.G., O'Fallon W.M., Gabriel S.E. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?. Ann Intern Med 1994, 120:987-992.
101. Niederkohr R.D., Levin L.A. Management of the patient with suspected temporal arteritis a decision-analytic approach. Ophthalmology 2005, 112:744-756.
102. Hayreh S.S., Podhajsky P.A., Raman R., Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997, 123:285-296.
103. Schmidt W.A., Kraft H.E., Volker L., Vorpahl K., Gromnica-Ihle E.J. Colour Doppler sonography to diagnose temporal arteritis. Lancet 1995, 345:866.
104. Arida A., Kyprianou M., Kanakis M., Sfikakis P.P. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musculoskelet Disord 2010, 11:44.
105. Ball E.L., Walsh S.R., Tang T.Y., Gohil R., Clarke J.M. Role of ultrasonography in the diagnosis of temporal arteritis. Br J Surg 2010, 97:1765-1771.
106. Alberts M.S., Mosen D.M. Diagnosing temporal arteritis: duplex vs. biopsy. QJM 2007, 100:785-789.
107. Bley T.A., Reinhard M., Hauenstein C., Markl M., Warnatz K., Hetzel A., et al. Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis. Arthritis Rheum 2008, 58:2574-2578.
108. Aschwanden M., Kesten F., Stern M., Thalhammer C., Walker U.A., Tyndall A., et al. Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2x11 arterial regions. Ann Rheum Dis 2010, 69:1356-1359.
109. 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2011, 38:1764-1772.
110. Blockmans D., Bley T., Schmidt W. Imaging for large-vessel vasculitis. Curr Opin Rheumatol 2009, 21:19-28.
111. Lehmann P., Buchtala S., Achajew N., Haerle P., Ehrenstein B., Lighvani H., et al. 18F-FDG PET as a diagnostic procedure in large vessel vasculitis-a controlled, blinded re-examination of routine PET scans. Clin Rheumatol 2011, 30:37-42.
112. Dasgupta B., Borg F.A., Hassan N., Alexander L., Barraclough K., Bourke B., et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford) 2010, 49:1594-1597.
113. Hayreh S.S., Zimmerman B., Kardon R.H. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002, 80:355-367.
114. Danesh-Meyer H., Savino P.J., Gamble G.G. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005, 112:1098-1103.
115. Hayreh S.S., Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003, 110:1204-1215.
116. Kupersmith M.J., Langer R., Mitnick H., Spiera R., Spiera H., Richmond M., et al. Visual performance in giant cell arteritis (temporal arteritis) after 1year of therapy. Br J Ophthalmol 1999, 83:796-801.
117. Chan C.C., Paine M., O'Day J. Steroid management in giant cell arteritis. Br J Ophthalmol 2001, 85:1061-1064.
118. Liu G.T., Glaser J.S., Schatz N.J., Smith J.L. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology 1994, 101:1779-1785.
119. Martinez-Lado L., Calviño-Diaz C., Piñeiro A., Dierssen T., Vazquez-Rodriguez T.R., Miranda-Filloy J.A., et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore) 2011, 90:186-193.
120. García-Martínez A., Hernández-Rodríguez J., Espígol-Frigolé G., Prieto-González S., Butjosa M., Segarra M., et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res (Hoboken) 2010, 62:835-841.
121. Andersson R., Malmvall B.E., Bengtsson B.A. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 1986, 220:465-469.
122. Proven A., Gabriel S.E., Orces C., O'Fallon W.M., Hunder G.G. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003, 49:703-708.
123. Mazlumzadeh M., Hunder G.G., Easley K.A., Calamia K.T., Matteson E.L., Griffing W.L., et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006, 54:3310-3318.
124. Chevalet P., Barrier J.H., Pottier P., Magadur-Joly G., Pottier M.A., Hamidou M., et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000, 27:1484-1491.
125. Hachulla E., Boivin V., Pasturel-Michon U., Fauchais A.L., Bouroz-Joly J., Perez-Cousin M., et al. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol 2001, 19:171-176.
126. Nuenninghoff D.M., Hunder G.G., Christianson T.J., McClelland R.L., Matteson E.L. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50years. Arthritis Rheum 2003, 48:3522-3531.
127. Schmidt W.A., Moll A., Seifert A., Schicke B., Gromnica-Ihle E., Krause A. Prognosis of large-vessel giant cell arteritis. Rheumatology (Oxford) 2008, 47:1406-1408.
128. García-Martínez A., Hernández-Rodríguez J., Arguis P., Paredes P., Segarra M., Lozano E., et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum 2008, 59:422-430.
129. Nuenninghoff D.M., Hunder G.G., Christianson T.J., McClelland R.L., Matteson E.L. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50years. Arthritis Rheum 2003, 48:3532-3537.
130. Evans J.M., O'Fallon W.M., Hunder G.G. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995, 122:502-507.
131. Gonzalez-Gay M.A., Garcia-Porrua C., Pineiro A., Pego-Reigosa R., Llorca J., Hunder G.G. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore) 2004, 83:335-341.
132. Nesher G., Sonnenblick M., Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994, 21:1283-1286.
133. Mahr A.D., Jover J.A., Spiera R.F., Hernandez-Garcia C., Fernandez-Gutierrez B., Lavalley M.P., et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007, 56:2789-2797.
134. Ytterberg S.R., Warrington K.J., Daniel A., Thomas B. Vasculitis working group: selected unanswered questions related to giant cell arteritis and anti-neutrophil cytoplasmic antibody-associated vasculitis. Joint Bone Spine 2009, 76:440-443.
135. De Silva M., Hazleman B.L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986, 45:136-138.
136. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., Merkel P.A., Weyand C.M., Stone J.H., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007, 146:621-630.
137. Martinez-Taboada V.M., Rodriguez-Valverde V., Carreno L., Lopez-Longo J., Figueroa M., Belzunegui J., et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008, 67:625-630.
138. Nesher G., Berkun Y., Mates M., Baras M., Rubinow A., Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004, 50:1332-1337.
139. Lee M.S., Smith S.D., Galor A., Hoffman G.S. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006, 54:3306-3309.
140. Gonzalez-Gay M.A., Piñeiro A., Gomez-Gigirey A., Garcia-Porrua C., Pego-Reigosa R., Dierssen-Sotos T., et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004, 83:342-347.
141. Weyand C.M., Kaiser M., Yang H., Younge B., Goronzy J.J. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002, 46:457-466.
142. Ninan J., Nguyen A.M., Cole A., Rischmueller M., Dodd T., Roberts-Thomson P., et al. Mortality in patients with biopsy-proven giant cell arteritis: a South Australian population-based study. J Rheumatol 2011.
143. Crow R.W., Katz B.J., Warner J.E., Alder S.C., Zhang K., Schulman S., et al. Giant cell arteritis and mortality. J Gerontol A Biol Sci Med Sci 2009, 64:365-369.
144. Bisgård C., Sloth H., Keiding N., Juel K. Excess mortality in giant cell arteritis. J Intern Med 1991, 230:119-123.
145. Uddhammar A., Eriksson A.L., Nyström L., Stenling R., Rantapää-Dahlqvist S. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002, 29:737-742.
146. Liozon F., Vidal E., Gaches F., Venot J., Liozon E., Cransac M., et al. Les décès dans la maladie de Horton. Facteurs de prognostic. Rev Med Interne 1992, 13:187-191.
147. Gonzalez-Gay M.A., Lopez-Diaz M.J., Martinez-Lado L., Pena-Sagredo J.L., Lopez-Agreda H., Miranda-Filloy J.A., et al. Cancer in biopsy-proven giant cell arteritis. A population-based study. Semin Arthritis Rheum 2007, 37:156-163.
148. Smith C.A., Fidler W.J., Pinals R.S. The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County, Tennessee. Arthritis Rheum 1983, 26:1214-1219.
149. Petursdottir V., Johansson H., Nordborg E., Nordborg C. The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology (Oxford) 1999, 38:1208-1212.
150. Gonzalez-Gay M.A., Barros S., Lopez-Diaz M.J., Garcia-Porrua C., Sanchez-Andrade A., Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 2005, 84:269-276.